Alerta

CONTROL OF NANOCAGE SELF-ASSEMBLY

Resumen de: WO2024110757A1

The invention provides constructs, pharmaceutical compositions, methods of preparing a ferritin nanocage, ferritin nanocages, methods of treating or preventing a disease in a subject, and methods of raising an immune response against an antigen. Exemplary constructs include two ferritin subunits connected by a linker, wherein the linker includes a cleavage site, wherein the linker is arranged to prevent the ferritin subunits from self-assembling into a ferritin nanocage, and wherein cleavage of the linker at the cleavage site does not prevent the ferritin subunits from self-assembling into a ferritin nanocage.

USE OF NANO-CARRIERS FOR DELIVERY OF ACTIVE AGENTS

Resumen de: US2025268840A1

There are disclosed methods of treating a subject or an object in need thereof, the method comprising administering compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub-micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.

NOVEL CARRIERS FOR NUCLEIC ACID AND/OR PROTEIN DELIVERY

Resumen de: WO2024110492A1

The invention relates to a carrier comprising at least one polar cationizable domain (PCD), two or more apolar cationizable domains (ACD) and at least one branching connector (BC), wherein the two or more ACDs are linked by at least one branching connector to at least one PCD, wherein the PCD is an oligo(alkylamino) acid, an ε-poly-L-lysine or an ε-poly-L-lysine-6-Ahx, and the ACD is a lipo amino fatty acid (LAF) comprising a tertiary amine. The invention further relates to nanoparticles comprising said carrier and a cargo, wherein the cargo comprises a nucleic acid and/or a protein and to a pharmaceutical composition comprising said nanoparticles and to its use in therapy or in in vitro culture.

IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF

Resumen de: CN120225501A

The present invention provides an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer of any of them; a lipid nanoparticle comprising the ionizable lipid (in particular as an encapsulant), optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticles. The present invention also provides a lipid nanoparticle for a drug or a pharmaceutical composition comprising the same, and a use of the lipid nanoparticle as an encapsulant. # imgabs0 #

METHOD OF TREATING OPERATIVE COMPLICATIONS OF CATARACT SURGERY

Resumen de: MX2025011000A

The present disclosure provides a method of treating or ameliorating an operative complication of a cataract surgery. The method comprises administering nanoparticles of clobetasol propionate to a subject in need thereof.

NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

Resumen de: MX2025010536A

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use in human or veterinary medicine, in particular for use in the treatment and/or prophylaxis of cancer diseases.

COMPOSITIONS AND METHODS FOR TREATING HYPERPROCALCITONEMIA

Resumen de: MX2025008776A

A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and /or liposomes organized as a lipid bilayer and/or other particle configurations.

NANOPARTICLE DISPERSIONS COMPRISING THERAPEUTIC AGENTS

Resumen de: AU2023385865A1

Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.

INHIBITORY NUCLEIC ACIDS AND METHODS OF USE THEREOF

Resumen de: CN120359038A

The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various diseases.

CANCER CYTOTOXIC EXOSOME FORMULATIONS AND METHODS FOR USE IN TREATING CANCER

TARGETED DELIVERY OF GENE EDITING CONSTRUCTS AND METHODS OF USE THEREOF

Resumen de: CN120390657A

The present invention relates to compositions for efficient delivery of gene editing agents to target cells, and methods of using the same to treat diseases or conditions.

IONIZABLE LIPID AND USE THEREOF

Resumen de: EP4624460A1

Provided in the present invention are an ionizable lipid, and a drug delivery system containing the ionizable lipid. Specifically, provided in the present invention is an ionizable lipid having the structure of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.

CARBAMATE-BOND-CONTAINING LIPID COMPOUNDS AND USE THEREOF

Resumen de: EP4624451A1

The present invention belongs to the field of biomedicine, which discloses a class of lipid compounds containing carbamate bond and applications thereof. The lipid compounds have the following structures:wherein the definitions of the various groups are described in the specification. The lipid nanoparticulate carriers prepared from the compounds described in the present invention exhibit excellent biocompatibility and safety as well as unexpected improvements in transfection efficiency, making them suitable for biomedical industrialization.

NOVEL TUMOR-SPECIFIC ANTIGENS FOR LYMPHOID LEUKEMIA AND USES THEREOF

Resumen de: WO2024108303A1

Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor, with only 30-40% of adult patients with ALL achieving long-term remission. Novel tumor-specific antigens (TSAs) shared by a large proportion of lymphoid leukemia cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as lymphoid leukemia is also described.

METHODS AND AGENTS FOR TREATING NEUROTROPHIC KERATITIS

Resumen de: WO2024102746A1

Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.

マルチアゴニストおよびその使用

Resumen de: US2025129135A1

The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.

Antimicrobial composition

Resumen de: GB2639579A

An antimicrobial composition comprising an antimicrobial compound and a population of metal nanoparticles is provided. The antimicrobial compound is preferably an antibiotic. The metal nanoparticle may comprise silver and/or copper and may also comprise a polymer coating such as poly(N-vinylpyrrolidone). The antimicrobial composition wherein the population of silver nanoparticles is formed by (a) mixing a first aqueous alkaline solution with an aqueous polymer solution to form an aqueous polymer solution; and (b) mixing the aqueous alkaline polymer solution with an aqueous solution of a metal salt to form a solution of polymer-coated metal nanoparticles is provided. A coating or treatment for a surface or substrate comprising the antimicrobial composition is provided. A medical device comprising the coating or treatment is provided. The medical device may be a wound care dressing or a bandage. A silver nanoparticle coated with poly(N-vinylpyrrolidone) is exemplified. Combinations of the PVP-coated silver nanoparticles (AgNP) and various antibiotics were tested. Compositions comprising silver nanoparticles and aminoglycosides, such as kanamycin and gentamicin, were particularly effective. A combination of silver nanoparticles and ebselen was also particularly effective against E. coli and S. aureus.

COMPOSITIONS OF DRY POWDER FORMULATIONS OF MESSENGER RNA AND METHODS OF USE THEREOF

Resumen de: CN120265279A

The present disclosure provides stable dry powder messenger RNA formulations for therapeutic use and methods of making and using the same.

治療剤の送達のための硫黄含有イオン化脂質

Resumen de: CN120051455A

Novel sulfur-containing lipids and nanoparticles containing the lipids and cargo molecules, such as nucleic acids, methods of formulating the lipids with nucleic acids to produce lipid nanoparticles, and chemical pathways for preparing the lipids, are provided. The lipid may have a structure of Formula A as defined herein. # imgabs0 #

ｍｉＲＮＡを有するトランス増幅ＲＮＡベクターを含むシステムおよび組成物

Resumen de: CN120239748A

The present invention encompasses systems, kits, and compositions comprising two RNA molecules wherein a first RNA molecule comprises an open reading frame encoding a functional RNA dependent RNA polymerase (replicase), and wherein a second RNA molecule is a replicable RNA molecule comprising at least one miRNA sequence that, when present in a cell, is capable of being cleaved from the second replicable RNA, and wherein the second RNA molecule is a replicable RNA molecule that comprises at least one miRNA sequence that, when present in the cell, is capable of being cleaved from the second replicable RNA. The first RNA molecule is capable of replication and is capable of modulating gene expression in a cell, and the replicable RNA molecule is capable of trans-replication by a replicase encoded by the first RNA molecule. The invention also encompasses methods of treating or preventing cancer or infections or other diseases and disorders with such systems and compositions, and the use of such systems and compositions in such methods of treatment and prevention.

癌を治療するためのＩＬ－１２遺伝子治療と抗ＶＥＧＦとの併用

Resumen de: WO2024054855A1

The present disclosure relates to a combination therapy comprising an anti-VEGF antibody, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.

水性分配カプセル

Resumen de: AU2023342067A1

Aqueous partitioning peptide capsules for delivery of active agents. The capsules comprise a membrane having an exterior surface and defining a liquid-receiving interior space configured to encapsulate water-soluble active agents therein. The capsule membrane consists of a plurality of linear peptides, each peptide comprising a hydrophobic core of between 4 and 12 hydrophobic amino acids flanked by N- and C-terminal hydrophilic segments each comprising between 3 to 4 hydrophilic amino acids. Methods of making peptide capsules and methods of using the peptide capsules to deliver active agents encapsulated therein or attached thereto to a variety of organisms is described.

NOVEL LIPIDS BASED ON OLIGO-Y-GLUTAMIC ACID DERIVATIVES AND LIPID NANOPARTICLES CONTAINING THE SAME, AND USES THEREOF

Resumen de: EP4624516A1

Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability.

SENP SENPDS SENP and SENPDS manufactured from active ingredients and method for manufacturing the same

Resumen de: KR20250142185A

본 발명은 활성성분을 포집한 나노입자(Nanoparticles, NP)와 자가유화 용액(Self-emulsifying solution, SES)으로부터 제조된 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제공한다. 경구 투여된 SENPDS는 위장관에서 수성 매체에 희석되면서 형성되는 NP 함유 지질방울은 전신 순환계에 유입되고 체류하면서 활성성분을 지속 방출할 수 있다. 이 과정에서 상기 온전한 NP 함유 지질방울은 자가소수성 반전 및 자가전하 반전을 포함하는 생체장벽 회피 전략으로 활성성분의 생체이용률이 향상됨을 확인하였다. 따라서, 본 발명의 SENPDS는 생체이용률이 향상된 의약품, 건강기능식품 및 화장품을 제공할 수 있다.

SENP SENPDS SENP and SENPDS manufactured from active ingredients and method for manufacturing the same

Nº publicación: KR20250142178A 30/09/2025

Solicitante:

김성천

Resumen de: KR20250142178A

본 발명은 활성성분을 포함하는 균질하고 견고한 폴리머 복합체 나노입자(Polymer Complexes Nanoparticles, PMNP)와 자가유화 용액(Self-emulsifying solution, SES)로부터 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 비침습적 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제안하였다. 본 발명의 상기 SENPDS는 3중 다층 구조체로 생체 내에서 견고한 PMNP 함유 오일방울로 전환하여 자가소수성 반전 및 자가전하 반전을 하여 기존 SNEDDS(Self-nanoemulsifying drug delivery system)와 다른 생체장벽 회피 전략으로 향상된 생체이용률을 확인하였다. 본 발명은 SENP, SENPDS 및 이들의 제조 방법에 관한 것이다.